John  Morris

John Charles Morris

Professor of Medicine, Co-Director, Comprehensive Lung Cancer Center, Associate Director, UCCI Translational Research and Director, Experimental Therapeutics

Vontz Center

1318

COM IM Hematology/Oncology Division - 0562

Vontz Center for Molecular Studies
3125 Eden Avenue
Cincinnati, Ohio 45267

Education

Medical Degree, Upstate Medical Center College of Medicine 1982

Internship, Mount Sinai Hospital 1983 (Internal Medicine)

Residency, Mount Sinai Hospital 1986 (Internal Medicine )

Fellowship, Mount Sinai Hospital 1988 (Medical Oncology)

Fellowship , Mount Sinai Hospital 1988 (Neoplastic Diseases)

Post-Doctoral Fellowship, National Institutes of Health 1999 (IPA Clinical Gene Therapy )

Bachelor's Degree, City University of New York 1978 (Biology)

Positions and Work Experience

11-2010 -To Present Professor, Division of Hematology/Oncology Department of Medicine, University of Cincinnati, Cincinnati, OH

07-2006 -10-2010 Staff Clinician, Metabolism Branch Center for Cancer Research, National Cancer Institute, Bethesda, MD

06-1999 -06-2006 Investigator, Metabolism Branch Center for Cancer Research, National Cancer Institute, Bethesda, MD

07-1992 -06-1999 Assistant Professor, Division of Neoplastic Diseases Department of Medicine, Mount Sinai School of Medicine, New York, New York

07-1990 -06-1992 Assistant Professor, Department of Neoplastic Diseases, Mount Sinai School of Medicine, New York, New York

07-1988 -06-1990 Clinical Instructor, Department of Neoplastic Diseases, Mount Sinai School of Medicine, New York, New York

07-1988 -06-1992 Clinical Instructor, Department of Medicine, Mount Sinai School of Medicine, New York, New York

11-2010 -To Present Attending Physician, University of Cincinnati Health/University Hospital/Barrett Cancer Center, Cincinnati, OH

11-1995 -10-2010 Staff Clinician, Mark O. Hatfield Clinical Research Center, National Institutes of Health, Bethesda, MD

07-1992 -06-1999 Assistant Attending, Division of Neoplastic Diseases, Mount Sinai Hopital, New York, New York

07-1990 -06-1992 Assistant Attending, Department of Neoplastic Diseases, Mount Sinai Hospital, New York, New York

07-1988 -06-1992 Clinical Attending, Department of Medicine, Mount Sinai Hospital, New York, New York

07-1988 -06-1990 Clinical Attending, Department of Neoplasstic Diseases, Mount Sinai Hospital, New York, New York

Research and Practice Interests

Lung, translational research, Phase I and II clinical trials, experimental therapeutics, immune therapy strategies, Hematology Oncology

UC Health Clinical Focus

Medical Oncology

Hematology and Oncology

UC Health Specialities

Internal Medicine

Medical Oncology

Research Support

Grant: #SRS006661 Investigators:Morris, John; Oleksowicz, Leslie 01-01-2009 -12-31-2013 National Cancer Institute Southwest Oncology Group- SWOG Role:PI $195,653.00 Active Level:Federal

Grant: #SRS006662 Investigators:Morris, John; Oleksowicz, Leslie 01-01-2009 -06-30-2014 National Cancer Institute Southwest Oncology Group- Clinical Trials Initiative Role:PI $43,479.00 Active Level:Federal

Grant: #RE11-00799 Investigators:Morris, John; Rixe, Olivier 01-01-2012 -12-31-2012 Greater Cincinnati Foundation Experimental Therapeutics Program at the University of Cincinnati Cancer Institute (UCCI) Role:PI $2,476.33 Closed Level:Private Non-Profit

Grant: #SWOG Purchase Service Agreement \ U10 CA037429 Investigators:Morris, John 06-09-2014 -05-21-2024 National Cancer Institute SWOG Purchase Service Agreement Role:PI $42,871.00 Awarded Level:Federal

Publications

Peer Reviewed Publications

Desai J.; Desai P.B.; Gulati S.; Gutkind J.S.; Jandarov R.; Mierzwa M.; Molinolo A.; Morris J.C.; Palackdharry S.M.; Riaz M.K.; Sadraei N.H.; Takiar V.; Wise-Draper T.M.; Zhu Z. (01-15-2020. )Phase 1 dose-finding study of metformin in combination with concurrent cisplatin and radiotherapy in.Cancer, ,126 (2 ),354-362

Ballas M.; Blumenthal G.; DeChowdhury R.; Dennis P.; Fioravanti S.; Hewitt S.; Hornyak T.; Komiya T.; Memmott R.; Morris J.; Morrow B.; Rajan A.; Wank S. (12-01-2019. )A Pilot Study of Sirolimus in Subjects with Cowden Syndrome or Other Syndromes Characterized by Germ.Oncologist, ,24 (12 ),1510-e1265

Bajars M.; Borel C.; Chaves J.; Guenther S.; Gulley J.L.; Kotecki N.; Morris J.C.; Peguero J.; Ravaud A.; Schöffski P.; Smakal M.; Vaishampayan U.; Zhou D. (10-24-2019. )Avelumab monotherapy as first-line or second-line treatment in patients with metastatic renal cell c.Journal for ImmunoTherapy of Cancer, ,7 (1 ),

Brzezniak C.E.; Hirth J.A.; I. Spira A.; Ma P.C.; Morgensztern D.; Morris J.; Padda S.K.; Padmanabhan A.; Reid T.; Rose M.; Trepel J.B.; Waqar S.N.; Zeman K.G. (07-30-2019. )RRx-001 followed by platinum plus etoposide in patients with previously treated small-cell lung canc.British Journal of Cancer, ,121 (3 ),211-217

A Hassan A.; Abouarab A.; Baudo M.; D'Ascenzo F.; Eldessouki I.; Elmously A.; Gaber O.; Gaudino M.; Ghaly G.; Girardi L.; Gray K.D.; Kamal M.; Kamel M.; Karim N.A.; Mohamed A.; Morris J.; Rahouma M.; Saad I.; Yahia M. (05-15-2019. )Cardiotoxicity with immune system targeting drugs: A meta-analysis of anti-PD/PD-L1 immunotherapy ra.Immunotherapy, ,11 (8 ),725-735

Adashek J.; Bergerot P.; Boyd T.; Carret A.; Chhabra S.; Forero-Torres A.; Gartner E.; Hoimes C.; Li H.; Morris J.; Pal S.; Smith D.; Thompson J.; Vogelzang N.; Yu X. (04-01-2019. )A phase 1 trial of SGN-CD70A in patients with CD70-positive, metastatic renal cell carcinoma.Cancer, ,125 (7 ),1124-1132

Acosta-Rivera M.; Adkins D.R.; Aghmesheh M.; Ahn M.J.; Airoldi M.; Aleknavicius E.; Al-Farhat Y.; Algazi A.P.; Almokadem S.; Alyasova A.; Bauman J.R.; Benasso M.; Berrocal A.; Bray V.; Burtness B.; Burtness B.A.; Caponigro F.; Castro A.; Cescon T.P.; Chan K.; Chaudhry A.; Chauffert B.; Cheng J.; Cohen E.; Cohen E.E.W.; Csoszi T.; De Boer J.P.; Delord J.P.; Dietz A.; Digue L.; Dinis J.; Dupuis C.; Erfan J.; Escobar Alvarez Y.; Evans M.; Fidler M.J.; Forster M.D.; Friesland S.; Ganti A.K.; Geoffrois L.; Grant C.; Gruenwald V.; Harrington K.; Harrington K.J.; Hoffmann T.; Horvai G.; Inciura A.; Jang R.; Jankowska P.; Jimeno A.; Joseph M.; Juarez Ramiro A.; Karaszewska B.; Kawecki A.; Keilholz U.; Keller U.; Kim S.B.; Kocsis J.; Kotecki N.; Kozloff M.F.; Lambea J.; Landherr L.; Lantsukhay Y.; Lazarev S.A.; Le Tourneau C.; Lee L.W.; Licitra L.; Lifirenko I.D.; Mach N.; Machiels J.P.; Martincic D.; Matorin O.V.; McGrath M.; Mehra R.; Misiukiewicz K.; Morris J.C.; Mufazalov F.F.; Niu J.; Pamoorthy Srinivasan D.; Perez Segura P.; Rauch D.; Ribeiro M.L.; Rodriguez C.; Rolland F.; Russo A.; Ruzsa A.; Sanches F.; Shin S.W.; Shtiveland M.; Soria A.; Soulières D.; Specenier P.; Swaby R.F.; Szekanecz E.; Szota J.; van Herpen C.M.L.; Velez-Cortes H.A.; Zhang P. (01-12-2019. )Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck.The Lancet, ,393 (10167 ),156-167

Abu-Asab M.; Morris J.; Morrison B.; Steel J. (01-01-2019. )Localization of human recombinant adenoviral vectors to the mitochondria following transduction of h.Acta virologica, ,63 (1 ),111-116

Abdel-Karim N.; Bahassi E.M.; Eldessouki I.; Gaber O.; Morris J. (01-01-2019. )Exosomes as a surrogate marker for autophagy in peripheral blood, correlative data from phase i stud.Asian Pacific Journal of Cancer Prevention, ,20 (12 ),3789-3796

Eldessouki I.; Gaber O.; Hassan R.; Karim N.; Magdy M.; Morris J. (01-01-2019. )Retrospective study of the effect of statins on the outcome of lung cancer patients, University of C.Asian Pacific Journal of Cancer Prevention, ,20 (8 ),2391-2396

Abouarab A.; Baudo M.; Cheriat A.N.; Eldessouki I.; Elmously A.; Gaudino M.; Ghaly G.; Gray K.D.; Kamel M.; Karim N.A.; Mohamed A.; Morris J.; Rahouma M.; Yahia M. (01-01-2019. )Pneumonitis as a complication of immune system targeting drugs?—a meta-analysis of anti-PD/PD-L1 imm.Journal of Thoracic Disease, ,11 (2 ),521-534

Berzofsky J.; Morris J.; Pastan I.; Stroncek D.; Terabe M.; Trepel J.; Wood L. (12-01-2018. )Cancer vaccine strategies: translation from mice to human clinical trials.Cancer Immunology, Immunotherapy, ,67 (12 ),1863-1869

Adkins D.R.; Bauman J.E.; Bowles D.W.; Cohen E.E.W.; Dietsch G.N.; Fenton M.; Ferris R.L.; Gibson M.; Gitlitz B.J.; Gottardo R.; Haddad R.; Hershberg R.M.; Jimeno A.; Kyle Bryan J.; Manjarrez K.L.; Misiukiewicz K.; Morris J.C.; Neupane P.; Nwizu T.; Saba N.F.; Sacco A.G.; Schneider C.J.; Shirai K.; Sukari A. (11-01-2018. )Effect of adding motolimod to standard combination chemotherapy and cetuximab treatment of patients .JAMA Oncology, ,4 (11 ),1583-1588

Becerra C.; Conkling P.; Dong Q.; Kellerman A.; Kingsley E.; Kolibaba K.; Laille E.; Morris J.; Rifkin R.; Savona M.; Skikne B.; Ukrainskyj S. (10-01-2018. )Extended dosing with CC-486 (oral azacitidine) in patients with myeloid malignancies.American Journal of Hematology, ,93 (10 ),1199-1206

Abouarab A.; Altorki N.K.; Eldessouki I.; Harrison S.; Kamel M.; Lee B.; Morris J.; Nasar A.; Port J.L.; Rahouma M.; Shostak E.; Stiles B. (08-16-2018. )Lung cancer patients have the highest malignancy-associated suicide rate in USA: A population-based .ecancermedicalscience, ,12 ,

Morris J.; Morrison B.; Steel J. (04-26-2018. )Reduction of MHC-I expression limits T-lymphocyte-mediated killing of Cancer-initiating cells.BMC Cancer, ,18 (1 ),

Eldessouki I.; Gaber O.; Karim N.; Morris J.; Namad T.; Wang J. (01-01-2018. )Small or non-small cell lung cancer based therapy for treatment of large cell neuroendocrine cancer .Journal of Oncology, ,2018 ,

Eldessouki I.; Gaber O.; Karim N.A.; Morris J.C.; Namad T.; Schuster J.; Wang J.; Xie C. (01-01-2018. )Pulmonary sarcomatoid carcinoma: University of Cincinnati experience.Oncotarget, ,9 (3 ),4102-4108

Butler R.; Casper K.; Lane A.; Mark J.; Morris J.; Palackdharry S.; Patil Y.; Pease N.; Privette Vinnedge L.; Qualtieri J.; Sadraei N.; Sendilnathan A.; Takiar V.; Wilson K.; Wise-Draper T. (01-01-2018. )Decreased plasma DEK Oncogene Levels Correlate with p16-Negative Disease and Advanced Tumor Stage in.Translational Oncology, ,11 (1 ),168-174

Haque S.; Morris J. (08-03-2017. )Transforming growth factor-?: A therapeutic target for cancer.Human Vaccines and Immunotherapeutics, ,13 (8 ),1741-1750

Lin Y.; Morris J.; Zandvakili I.; Zheng Y. (06-08-2017. )Rho GTPases: Anti-or pro-neoplastic targets?.Oncogene, ,36 (23 ),3213-3222

Beg M.; Desai P.; Fathallah H.; Karim N.; Kozma S.; Mercer C.; Moorthy G.; Morris J.; O’Gara S.; Olowokure O.; Rixe O.; Salkeni M.; Thomas G.; Thomas H.; Wise-Draper T. (06-01-2017. )A Phase Ib Study of the Dual PI3K/mTOR Inhibitor Dactolisib (BEZ235) Combined with Everolimus in Pat.Targeted Oncology, ,12 (3 ),323-332

Clot P.F.; He A.; Hsueh C.T.; Hwang J.; Lockhart A.C.; Mier J.; Mita A.C.; Morris J.C.; Quinn D.I.; Rixe O.; Sarantopoulos J.; Wack C.; Wade J.L.; Yin J.; Zhang W. (02-01-2017. )Safety and pharmacokinetics of cabazitaxel in patients with hepatic impairment: a phase I dose-escal.Cancer Chemotherapy and Pharmacology, ,79 (2 ),339-351

Fleisher T.; Jaffe E.; Janik J.; Lee C.; Morris J.; O'Mahony D.; Pittaluga S.; Raffeld M.; Sharma K.; Steinberg S.; Stetler-Stevenson M.; Stewart D.; Waldmann T. (01-01-2017. )Phase II study of alemtuzumab (CAMPATH-1) in patients with HTLV-1-associated adult T-cell leukemia/l.Clinical Cancer Research, ,23 (1 ),35-42

Bryan J.K.; Cohen E.; Dietsch G.N.; Ferris R.L.; Gitlitz B.; Haddad R.; Hershberg R.M.; Manjarrez K.L.; Misiukiewicz K.; Morris J.C.; Neupane P.; Saba N.F.; Sukari A. (10-01-2016. )immunotherapy of cancer Active8: A randomized, double-blind, placebo-controlled study of chemotherap.Annals of Oncology, ,27 ,vi573

Bonner W.M.; Brechbiel M.W.; Brown M.; Bryant B.R.; Carrasquillo J.A.; Chen C.; Conlon K.C.; Corcoran E.; Fioravanti S.; Fleisher T.A.; Goldman C.K.; Jaffe E.S.; Janik J.E.; Junghans R.P.; Lee C.C.; Lee J.H.; Morris J.C.; O'Mahony D.; Paik C.H.; Pittaluga S.; Redon C.E.; Stewart D.M.; Waldmann T.A.; Whatley M.; White J.D.; Worthy T. (10-20-2015. )90Y-daclizumab, an anti-CD25 monoclonal antibody, provided responses in 50% o.Proceedings of the National Academy of Sciences of the United States of America, ,112 (42 ),13045-13050

Cohen R.B.; Doroumian S.; Lo Russo P.M.; Morris J.C.; Olowokure O.O.; Olszanski A.J.; Puzanov I.; Rixe O.; Shen L.; Yin J.Y. (08-01-2015. )Phase i dose-escalation study of cabazitaxel administered in combination with gemcitabine in patient.Anti-Cancer Drugs, ,26 (7 ),785-792

Berzofsky J.; Dezube B.; Guitart J.; Hsu F.; Lacouture M.; Lawrence D.; Morris J.; Olencki T.; Shapiro G.; Tan A. (03-22-2015. )Cutaneous keratoacanthomas/squamous cell carcinomas associated with neutralization of transforming g.Cancer Immunology, Immunotherapy, ,64 (4 ),437-446

Allen C.; Bian Y.; Chen Z.; Morris J.; Van Waes C. (01-01-2015. )Squamous-cell carcinoma.Molecular Oncology: Causes of Cancer and Targets for Treatment, ,686-692

Ali S.M.; Morris J.C.; Pal S.K.; Palma N.; Ross J.S. (01-01-2015. )Exceptional response to pazopanib in a patient with urothelial carcinoma harboring FGFR3 activating .European Urology, ,68 (1 ),168-170

Berzofsky J.; Hogg A.; Kato S.; Morris J.; Steel J.; Sui Y.; Wang Y. (01-01-2015. )Vaginal type-II mucosa is an inductive site for primary CD8+ T-cell mucosal i.Nature Communications, ,6 ,

Bryant B.R.; Chen J.; Conlon K.C.; Creekmore S.P.; Decker J.M.; Dubois S.P.; Figg W.D.; Fleisher T.A.; Fojo A.T.; Goldman C.K.; Lane H.C.; Lugli E.; Morris J.C.; Peer C.J.; Perera L.P.; Roederer M.; Rosenberg S.A.; Sneller M.C.; Stewart D.M.; Waldmann T.A.; Welles H.C.; Worthy T.A.; Yovandich J.L. (01-01-2015. )Redistribution, hyperproliferation, activation of natural killer cells and CD8 T cells, and cytokine.Journal of Clinical Oncology, ,33 (1 ),74-82

Berkowitz J.; Figg W.; Fleisher T.; Goldman C.; Jaffe E.; Janik J.; Morris J.; Peer C.; Shih J.; Stetler-Stevenson M.; Stewart D.; Turner M.; Urquhart N.; Waldmann T.; Wharfe G. (12-01-2014. )Safety, efficacy, and pharmacokinetics/pharmacodynamics of daclizumab (anti-CD25) in patients with a.Clinical Immunology, ,155 (2 ),176-187

Berzofsky J.; Dezube B.; Hsu F.; Lawrence D.; Morris J.; Olencki T.; Reiss M.; Shapiro G.; Tan A. (03-11-2014. )Phase I study of GC1008 (Fresolimumab): A human anti-transforming growth factor-beta (TGF?) monoclon.PLoS ONE, ,9 (3 ),

Craig Lockhart A.; Dedieu J.F.; Kassalow L.; Mita A.C.; Mita M.M.; Morris J.C.; Rixe O.; Sarantopoulos J.; Wack C.; Wade J.L. (02-05-2014. )Phase i study of cabazitaxel plus cisplatin in patients with advanced solid tumors: Study to evaluat.Cancer Chemotherapy and Pharmacology, ,74 (6 ),1113-1124

Morris J.; Ramlogan-Steel C.; Steel J. (01-01-2014. )Lung cancer vaccines: Current status and future prospects.Translational Lung Cancer Research, ,3 (1 ),46-52

Allison J.; Black B.; Mannan P.; Morris J.; Ramlogan-Steel C.; Steel J.; Waldmann T.; Yu P. (01-01-2014. )Vaccination with tumor cells expressing IL-15 and IL-15R inhibits murine breast and prostate cancer.Gene Therapy, ,21 (4 ),393-401

Morris J.; Morrison B.; Steel J. (09-01-2013. )Lung cancer-initiating cells: A novel target for cancer therapy.Targeted Oncology, ,8 (3 ),159-172

Achyut B.; Day C.; Gara S.; Li Z.; Morris J.; Pang Y.; Trinchieri G.; Weiss J.; Yan H.; Yang L. (08-01-2013. )TGF-? Signaling in myeloid cells is required for tumor metastasis.Cancer Discovery, ,3 (8 ),936-951

Albert P.S.; Bryant B.R.; Conlon K.C.; Creekmore S.P.; Decker J.R.; Figg W.D.; Fleisher T.A.; Goldman C.K.; Janik J.E.; Morris J.C.; Petrus M.N.; Raffeld M.; Spencer S.D.; Stewart D.M.; Waldmann T.A.; Worthy T.Y.A. (07-17-2013. )Phase 1 trial of IL-15 trans presentation blockade using humanized Mik-Beta-1 mAb in patients with T.Blood, ,121 (3 ),476-484

Morris J.; Morrison B.; Steel J. (05-01-2013. )Immunotherapy in lung cancer: The potential of cancer stem cells in future therapies.Future Oncology, ,9 (5 ),623-625

Chiorini J.; Di Pasquale G.; Morris J.; Patel V.; Ramlogan C.; Steel J. (01-01-2013. )Oral vaccination with adeno-associated virus vectors expressing the Neu oncogene inhibits the growth.Molecular Therapy, ,21 (3 ),680-687

Chen J.; Conlon K.; Janik J.; Keating A.; Morris J.; Pise-Masison C.; Shih J.; Waldmann T. (01-01-2013. )Markedly additive antitumor activity with the combination of a selective survivin suppressant YM155 .Blood, ,121 (11 ),2029-2037

Morris J.C.; Morrison B.J.; Steel J.C. (12-07-2012. )Monoclonal antibodies for the treatment of cancer .Principles of Molecular Diagnostics and Personalized Cancer Medicine, ,580-593

Morris J.; Morrison B.; Steel J. (11-13-2012. )Sphere Culture of Murine Lung Cancer Cell Lines Are Enriched with Cancer Initiating Cells.PLoS ONE, ,7 (11 ),

Conlon K.; Janik J.E.; Kaushal A.; Kreitman R.J.; Lita E.; Morris J.C.; Simone C.B.; Stewart D.M.; Urquhart N.E.; Waldmann T.A.; Wharfe G. (08-30-2012. )Radiation therapy for the management of patients with HTLV-1-associated adult T-cell leukemia/lympho.Blood, ,120 (9 ),1816-1819

Hu M.; Janik J.; Larson T.; Morris J.; Nussenblatt R.; Sen H. (08-01-2012. )Interleukin-2 receptor targeted therapy of ocular disease of HTLV-1-associated adult T-cell leukemia.Ocular Immunology and Inflammation, ,20 (4 ),312-314

Allison J.; Fasso M.; Morris J.; Steel J.; Waitz R.; Waldmann T.; Yu P.; Zhang M. (04-17-2012. )Simultaneous inhibition of two regulatory T-cell subsets enhanced Interleukin-15 efficacy in a prost.Proceedings of the National Academy of Sciences of the United States of America, ,109 (16 ),6187-6192

Filie A.; Janik J.; Morris J.; Stetler-Stevenson M.; Tembhare P.; Yuan C. (02-01-2012. )Flow cytometric immunophenotypic assessment of T-cell clonality by V ? repert.American Journal of Clinical Pathology, ,137 (2 ),220-226

Bamford R.; Chen J.; Janik J.; Morris J.; Petrus M.; Shih J.; Waldmann T. (01-05-2012. )Increased serum soluble IL-15R? levels in T-cell large granular lymphocyte leukemia.Blood, ,119 (1 ),137-143

Morris J.; Steel J.; Waldmann T. (01-01-2012. )Interleukin-15 biology and its therapeutic implications in cancer.Trends in Pharmacological Sciences, ,33 (1 ),35-41

Anderson M.; Bridges J.; Kupert E.; Morris J.; Pathrose P.; Starnes S.; Succop P.; Wang J. (01-01-2012. )Clinical and molecular predictors of recurrence in stage i non-small cell lung cancer.Annals of Thoracic Surgery, ,93 (5 ),1606-1612

Aitova L.; Kaplanskaya I.; Maryin D.; Morris J.; Samoilova R.; Shklovskiy-Kordi N.; Sidorova Y.; Varticovski L.; Vinogradova Y.; Vorobiev A.; Vorobiev I.; Zingerman B. (01-01-2012. )Clinicopathological features and outcomes of T- and NK-cell lymphomas in european Russia.Clinical Medicine Insights: Blood Disorders, ,5 ,1-13

Fedorko D.; Janik J.; Mahanty S.; Morris J.; Ramanathan R.; Stewart D. (08-01-2011. )Disseminated Strongyloides stercoralis infection in HTLV-1-associated adult T-cell leukemia/lymphoma.Acta Haematologica, ,126 (2 ),63-67

Berkowitz J.; Janik J.; Morris J.; Pittaluga S.; Raffeld M.; Venkataraman G. (07-01-2011. )Adult T-cell leukemia/lymphoma with Epstein-Barr virus-positive Hodgkin-like cells.Human Pathology, ,42 (7 ),1042-1046

Janik J.; Liewehr D.; Morris J.; Raffeld M.; Stetler-Stevenson M.; Tembhare P.; Venzon D.; Xi L.; Yuan C. (06-01-2011. )Flow cytometric immunophenotypic assessment of T-cell clonality by V ? repert.American Journal of Clinical Pathology, ,135 (6 ),890-900

Citrin D.; Janik J.; Kelly R.; Lopez-Chavez A.; Morris J. (04-06-2011. )Impacting tumor cell-fate by targeting the inhibitor of apoptosis protein survivin.Molecular Cancer, ,10 ,

Bryant B.; Chen J.; Jacobson S.; Janik J.; Jiang J.; Ju W.; Morris J.; Oh U.; Sato N.; Tagaya Y.; Thomas C.; Waldmann T.; Zhang M. (02-10-2011. )CP-690,550, a therapeutic agent, inhibits cytokine-mediated Jak3 activation and proliferation of T c.Blood, ,117 (6 ),1938-1946

Abu-Asab M.; Alesci S.; Brouwers F.M.; Fojo A.T.; Kiesewetter D.O.; Kvetnansky R.; Martiniova L.; Marvelle A.F.; Morris J.C.; Pacak K.; Perera S.M.; Reynolds J.C.; Thomasson D.; Tischler A.S. (02-01-2011. )Increased uptake of [123I]meta-iodobenzylguanidine, [ 18.Endocrine-Related Cancer, ,18 (1 ),143-157

Bamford R.; Bryant B.; Chen J.; Goldman C.; Janik J.; Morris J.; Nguyen V.; Petrus M.; Waldmann T. (12-23-2010. )Autocrine/paracrine cytokine stimulation of leukemic cell proliferation in smoldering and chronic ad.Blood, ,116 (26 ),5948-5956

Morris J.; Steel J.; Waldmann T.; Yu P.; Zhang M. (12-15-2010. )Simultaneous blockade of multiple immune system inhibitory checkpoints enhances antitumor activity m.Clinical Cancer Research, ,16 (24 ),6019-6028

Gregory M.; Malyguine A.; Morris J.; Shurin M. (11-01-2010. )Genetically modified dendritic cells in cancer immunotherapy: A better tomorrow?.Expert Opinion on Biological Therapy, ,10 (11 ),1539-1553

Allen C.; Chen Z.; Citrin D.; Colevas A.; Dancey J.; Gius D.; Harold N.; Morris J.; Muir C.; Nottingham L.; Rudy S.; Singh A.; Van Waes C. (06-01-2010. )Molecular and Clinical Responses in a Pilot Study of Gefitinib With Paclitaxel and Radiation in Loca.International Journal of Radiation Oncology Biology Physics, ,77 (2 ),447-454

Anderson V.; Childs R.; Drusano G.; Henning S.; Holland S.; Moriyama B.; Morris J.; Walsh T.; Wilson W. (05-01-2010. )High-dose continuous infusion ?-lactam antibiotics for the treatment of resistant Pseudomonas aerugi.Annals of Pharmacotherapy, ,44 (5 ),929-935

Janik J.; Morris J.; Raffeld M.; Shao H.; Stetler-Stevenson M.; Xi L.; Yuan C. (04-01-2010. )Minimal residual disease detection by flow cytometry in adult T-cell leukemia/lymphoma.American Journal of Clinical Pathology, ,133 (4 ),592-601

Kelly R.; Morris J. (03-01-2010. )Transforming growth factor-beta: A target for cancer therapy.Journal of Immunotoxicology, ,7 (1 ),15-26

Forni G.; Morris J.; Ramlogan C.; Sakai Y.; Steel J.; Waldmann T.; Yu P. (02-01-2010. )Interleukin-15 and its receptor augment dendritic cell vaccination against the neu oncogene through .Cancer Research, ,70 (3 ),1072-1081

Janik J.; Morris J. (12-17-2009. )Survivin(g) adult T-cell leukemia/lymphoma .ONCOLOGY, ,23 (14 ),

Morris J.; Waldmann T. (12-01-2009. )Antibody-based therapy of leukaemia.Expert Reviews in Molecular Medicine, ,11 ,

Gregory M.; Malyguine A.; Morris J.; Morrison B.; Steel J. (12-01-2009. )Genetically modified dendritic cells in cancer immunotherapy.Dendritic Cells in Cancer, ,347-363

Brady J.; Dohoney K.; Janik J.; Lee M.; Morris J.; O'Mahony D.; Pise-Masison C.; Radonovich M.; Trepel J.; Waldmann T. (11-17-2009. )Gene expression profiling of ATL patients: Compilation of disease-related genes and evidence for TCF.Blood, ,113 (17 ),4016-4026

Janik J.; Morris J.; O'Mahony D.; Waldmann T. (09-09-2009. )Monoclonal antibody therapy of T cell lymphoma: Single agent trials of anti-CD2 (Siplizumab) and ant .Haematologica Meeting Reports, ,3 (1 ),61-68

Albert P.; Citrin D.; Colevas A.; Cooley-Zgela T.; Cotrim A.; Herscher L.; Likhacheva A.; Mansueti J.; Morris J.; Rudy S.; Russo A.; Sciuto L.; Smith S.; Solomon B.; Van Waes C. (07-15-2009. )Long-Term Outcomes and Toxicity of Concurrent Paclitaxel and Radiotherapy for Locally Advanced Head-.International Journal of Radiation Oncology Biology Physics, ,74 (4 ),1040-1046

Hubacheck J.; Janik J.; Jasper G.; Jiang L.; Morris J.; Stetler-Stevenson M.; Wilson W.; Yuan C. (04-01-2009. )Variable CD52 expression in mature T cell and NK cell malignancies: Implications for alemtuzumab the.British Journal of Haematology, ,145 (2 ),173-179

Allen C.T.; Calvo K.R.; Chen Z.; Dabir B.; Friedman J.; Morris J.C.; Mundinger G.S.; Pernas F.G.; Saigal K.; Van Waes C.; Winters M.E.; Xu X.; Yan B. (04-01-2009. )Proteomic signatures of epidermal growth factor receptor and survival signal pathways correspond to .Clinical Cancer Research, ,15 (7 ),2361-2372

Albert P.; Brown M.; Fleisher T.; Hammershaimb L.; Janik J.; Kaucic K.; Matthews H.; Morris J.; O'Mahony D.; Pittaluga S.; Raffeld M.; Reitsma D.; Stetler-Stevenson M.; Waldmann T. (04-01-2009. )EBV-related lymphoproliferative disease complicating therapy with the anti-CD2 monoclonal antibody, .Clinical Cancer Research, ,15 (7 ),2514-2522

Abu-Asab M.; Alesci S.; Elkahloun A.; Huynh T.; Kvetnansky R.; Lai E.; Lubensky I.; Martiniova L.; Morris J.; Pacak K.; Perera S.; Solis D.; Tischler A.; Wickremasinghe A. (03-01-2009. )Characterization of an animal model of aggressive metastatic pheochromocytoma linked to a specific g.Clinical and Experimental Metastasis, ,26 (3 ),239-250

De Krijger R.; Dogra R.; Elkahloun A.; Fujisawa T.; Joshi B.; Lai E.; Leland P.; Lubensky I.; Martiniova L.; Morris J.; Pacak K.; Puri R. (01-01-2009. )Overexpression of interleukin-13 receptor-?2 in neuroendocrine malignant pheochromocytoma: A novel t.Journal of Clinical Endocrinology and Metabolism, ,94 (8 ),2952-2957

Cooley-Zgela T.; Gius D.; Morris J.; Sharp H.; Singh A.; Van Waes C. (12-01-2008. )High incidence of oral dysesthesias on a trial of gefitinib, paclitaxel, and concurrent external bea.American Journal of Clinical Oncology: Cancer Clinical Trials, ,31 (6 ),557-560

Balgley B.; Bornstein S.; Bratslavsky G.; Eisenhofer G.; Elkahloun A.; Huynh T.; Lee C.; Lenders J.; Linehan W.; Mannelli M.; Morris J.; Pacak K.; Zhuang Z. (11-01-2008. )Differential expression of the regulated catecholamine secretory pathway in different hereditary for.American Journal of Physiology - Endocrinology and Metabolism, ,295 (5 ),

Bamford R.; Bryant B.R.; Chen J.; Goldman C.K.; Janik J.E.; Morris J.C.; Nguyen V.P.; Petrus M.; Stamer M.; Waldmann T.A. (05-15-2008. )Induction of the IL-9 gene by HTLV-I Tax stimulates the spontaneous proliferation of primary adult T.Blood, ,111 (10 ),5163-5172

Janik J.; Morris J.; Waldmann T. (04-01-2008. )Receptor-directed therapy of T-cell leukemias and lymphomas.Journal of Immunotoxicology, ,5 (2 ),235-248

Chan W.; Green J.; Lai E.; Morris J.; Ohta S.; Pacak K.; Pang A.; Powers J.; Sirajuddin P.; Taniguchi S.; Tischler A.; Watanabe M.; Yazawa H.; Zhang R. (04-01-2008. )Metastasis-associated gene expression profile of liver and subcutaneous lesions derived from mouse p.Molecular Carcinogenesis, ,47 (4 ),245-251

Berzofsky J.; Forni G.; Jong M.; Morris J.; Sakai Y.; Steel J.; Terabe M. (03-15-2008. )Therapy of advanced established murine breast cancer with a recombinant adenoviral ErbB-2/neu vaccin.Cancer Research, ,68 (6 ),1979-1987

Aisner D.; Debnath I.; Jaffe E.; Janik J.; Morris J.; O'Mahony D.; Waldmann T. (03-01-2008. )Cardiac involvement with human T-cell lymphotrophic virus type-1-associated adult T-cell leukemia/ly.Leukemia and Lymphoma, ,49 (3 ),439-446

Abu-Asab M.; Mannan P.; Miles B.; Morris J.; Morrison B.; Prince G.; Ramanan V.; Steel J.; Wildner O.; Yim K. (12-05-2007. )Immunocompetent syngeneic cotton rat tumor models for the assessment of replication-competent oncoly.Virology, ,369 (1 ),131-142

Abu-Asab M.; Alesci S.; Morris J.; Pacak K.; Perera S.; Tsokos M. (12-01-2007. )Mitochondrial localization of human recombinant adenovirus: From evolution to gene therapy.NeuroImmunoModulation, ,14 (5 ),221-223

Abu-Asab M.; Alesci S.; Kukura C.; Lai E.; Morris J.; Pacak K.; Perera S.; Tsokos M. (08-01-2007. )Adenoviral gene transfer in bovine adrenomedullary and murine pheochromocytoma cells: Potential clin.Endocrinology, ,148 (8 ),3900-3907

Janik J.; Morris J. (06-01-2007. )Therapeutic immunotoxins for lymphoid malignancies: The end of the beginning.Leukemia and Lymphoma, ,48 (6 ),1067-1069

Abu-Asab M.; Burton M.; Cavanagh H.; Kalle W.; Morris J.; Steel J.; Tsokos M. (04-01-2007. )Increased tumor localization and reduced immune response to adenoviral vector formulated with the li.European Journal of Pharmaceutical Sciences, ,30 (5 ),398-405

Burke J.; Morris J. (03-01-2007. )Retroviral vectors encoding a reverse transcription-activated transgene efficiently limit expression.Molecular Therapy, ,15 (3 ),552-559

Albert P.; Brown M.; Davis T.; Fleisher T.; Gao W.; Gause B.; Gulley J.; Janik J.; Lowy I.; Morris J.; Neelapu S.; Nussenblatt R.; O'Mahony D.; Petrus M.; Pittaluga S.; Quinn C.; Schlom J.; Waldmann T.; Wilson W. (02-01-2007. )A pilot study of CTLA-4 blockade after cancer vaccine failure in patients with advanced malignancy.Clinical Cancer Research, ,13 (3 ),958-964

Abu-Asab M.; Bakan D.; Cleary S.; Klaunberg B.; Lai E.; Morris J.; Ohta S.; Pacak K.; Powers J.; Schimel D.; Tischler A. (11-01-2006. )MicroCT for high-resolution imaging of ectopic pheochromocytoma tumors in the liver of nude mice.International Journal of Cancer, ,119 (9 ),2236-2241

Morris J.; Waldmann T. (05-29-2006. )Development of Antibodies and Chimeric Molecules for Cancer Immunotherapy.Advances in Immunology, ,90 ,83-131

Brown M.; Bryant B.; Fleisher T.; Gao W.; Goldman C.; Janik J.; Lee C.; Morris J.; Petrus M.; Top L.; Tsudo M.; Waldmann T.; White J. (01-10-2006. )Preclinical and phase I clinical trial of blockade of IL-15 using Mik?1 monoclonal antibody in T cel.Proceedings of the National Academy of Sciences of the United States of America, ,103 (2 ),401-406

Adams J.; Camphausen K.; Chang A.A.; Chen Z.; Conley B.A.; Druzgal C.H.; Elsayed Y.A.; Gius D.; Lebowitz P.F.; Mitchell J.B.; Morris J.C.; Rudy S.F.; Sausville E.A.; Sunwoo J.B.; Van Waes C. (12-01-2005. )Inhibition of nuclear factor-?B and target genes during combined therapy with proteasome inhibitor b.International Journal of Radiation Oncology Biology Physics, ,63 (5 ),1400-1412

Albert P.; Chen Z.; Druzgal C.; Duffey D.; Ende K.; Herscher L.; McCullagh L.; Morris J.; Muir C.; Ondrey F.; Rudy S.; Thomas G.; Van Waes C.; Vilela R.; Yeh N. (09-01-2005. )A pilot study of longitudinal serum cytokine and angiogenesis factor levels as markers of therapeuti.Head and Neck, ,27 (9 ),771-784

Berzofsky J.; Forni G.; Morris J.; Munasinghe J.; Park J.; Sakai Y.; Terabe M. (04-01-2005. )Early role of CD4+ Th1 cells and antibodies in HER-2 adenovirus vaccine prote.Journal of Immunology, ,174 (7 ),4228-4236

Grant N.; Gutierrez M.; Jaffe E.; Janik J.; McDonald K.; Morris J.; Pittaluga S.; Raffeld M.; Waldmann T.; Wilson W. (11-15-2004. )Elevated serum-soluble interleukin-2 receptor levels in patients with anaplastic large cell lymphoma.Blood, ,104 (10 ),3355-3357

Berzofsky J.; Burke J.; Forni G.; Janik J.; Morris J.; Morrison B.; Park J.; Sakai Y.; Terabe M. (11-01-2004. )Vaccination by genetically modified dendritic cells expressing a truncated neu oncogene prevents dev.Cancer Research, ,64 (21 ),8022-8028

Ahlers J.; Belyakov I.; Berzofsky J.; Janik J.; Morris J.; Oh S.; Terabe M. (08-01-2004. )Progress on new vaccine strategies against chronic viral infections.Journal of Clinical Investigation, ,114 (4 ),450-462

Ehninger G.; Morris J.C.; Ramsey W.J.; Wolkersdörfer G.W. (06-01-2004. )Trans-complementing adenoviral vectors for oncolytic therapy of malignant melanoma.Journal of Gene Medicine, ,6 (6 ),652-662

Ajalli R.; Blaese R.; Caplen N.; Hamada H.; Kume A.; Morris J.; Nomoto T.; Okada T.; Onodera M.; Ozawa K.; Ramsey W.; Shimazaki K.; Wildner O. (03-01-2004. )In situ generation of pseudotyped retroviral progeny by adenovirus-mediated transduction of tumor ce.Journal of Gene Medicine, ,6 (3 ),288-299

Chan C.C.; Lee S.S.; Mirtsching B.C.; Morris J.C.; Robinson M.R.; Shen D.F. (01-01-2004. )Conjunctival involvement with T-cell prolymphocytic leukemia: Report of a case and review of the lit.Survey of Ophthalmology, ,49 (5 ),525-536

Ahlers J.; Belyakov I.; Berzofsky J.; Janik J.; Morris J.; Oh S.; Terabe M. (01-01-2004. )Progress on new vaccine strategies for the immunotherapy and prevention of cancer.Journal of Clinical Investigation, ,113 (11 ),1515-1525

Morris J. (06-01-2003. )Cancer gene therapy: Lessons learned from experiences with chemotherapy.Molecular Therapy, ,7 (6 ),717-719

Morris J.; Wildner O. (01-01-2002. )Subcutaneous administration of a replication-competent adenovirus expressing HSV-tk to cotton rats: .Human Gene Therapy, ,13 (1 ),101-112

Duray P.; Holland S.; Jaffe E.; Lei J.; Morris J.; Raffeld M.; Sorbara L.; Turner M.; Wang Y. (12-01-2000. )Microcystic adnexal carcinoma associated with primary immunodeficiency, recurrent diffuse herpes sim.American Journal of Dermatopathology, ,22 (6 ),524-529

Morris J.; Waldmann T. (11-20-2000. )Advances in interleukin 2 receptor targeted treatment .Annals of the Rheumatic Diseases, ,59 (SUPPL. 1 ),

Morris J.; Wildner O. (08-31-2000. )The role of the E1B 55 kDa gene product in oncolytic adenoviral vectors expressing herpes simplex vi .Cancer Research, ,60 (15 ),4167-4174

Aguilar-Cordova E.; Blaese R.; Morris J.; Muslow H.; Ramsey W.; Wildner O. (02-10-2000. )A phase I study of intralesional administration of an adenovirus vector expressing the HSV-1 thymidi.Human Gene Therapy, ,11 (3 ),487-503

Morris J.; Wildner O. (01-01-2000. )Therapy of peritoneal carcinomatosis from colon cancer with oncolytic adenoviruses.Journal of Gene Medicine, ,2 (5 ),353-360

Morris J.; Wildner O. (01-01-2000. )Therapy of Head and Neck Squamous Cell Carcinoma with an Oncolytic Adenovirus Expressing HSV-tk.Molecular Therapy, ,1 (1 ),56-62

Blaese R.; Morris J.; Wildner O. (11-01-1999. )Synergy between the herpes simplex virus tk/ganciclovir prodrug suicide system and the topoisomerase.Human Gene Therapy, ,10 (16 ),2679-2687

Blaese R.; Morris J.; Wildner O. (01-16-1999. )Therapy of colon cancer with oncolytic adenovirus is enhanced by the addition of herpes simplex viru .Cancer Research, ,59 (2 ),410-413

Blaese R.; Ford H.; Morris J.; Ramsey W.; Vahanian N.; Wildner O. (01-01-1999. )Adenoviral vectors capable of replication improve the efficacy of HSVtk/GCV suicide gene therapy of .Gene Therapy, ,6 (1 ),57-62

Bouvet, Michael; Reid, Tony R; Larson, Chris; Oronsky, Bryan; Carter, Corey; Morris, John C (2019. )Extended treatment with MY-NEOVAX, personalized neoantigen-enhanced oncolytic viruses, for two end-stage cancer patients.Oxford medical case reports, ,2019 (11 ),461-463

Rahouma, Mohamed; Baudo, Massimo; Yahia, Maha; Kamel, Mohamed; Gray, Katherine D; Elmously, Adham; Ghaly, Galal; Eldessouki, Ihab; Abouarab, Ahmed; Cheriat, Ali N; Karim, Naglaa Abdel; Mohamed, Abdelrahman; Morris, John; Gaudino, Mario (2019. )Pneumonitis as a complication of immune system targeting drugs?-a meta-analysis of anti-PD/PD-L1 immunotherapy randomized clinical trials.Journal of thoracic disease, ,11 (2 ),521-534

Eldessouki, Ihab; Gaber, Ola; Namad, Tariq; Wang, Jiang; Morris, John C; Abdel Karim, Nagla (2018. )Small or Non-Small Cell Lung Cancer Based Therapy for Treatment of Large Cell Neuroendocrine Cancer of The Lung? University of Cincinnati Experience.Journal of oncology, ,2018 ,9761826

Rahouma, Mohamed; Kamel, Mohamed; Abouarab, Ahmed; Eldessouki, Ihab; Nasar, Abu; Harrison, Sebron; Lee, Benjamin; Shostak, Eugene; Morris, John; Stiles, Brendon; Altorki, Nasser K; Port, Jeffrey L (2018. )Lung cancer patients have the highest malignancy-associated suicide rate in USA: a population-based analysis.Ecancermedicalscience, ,12 ,859

Wise-Draper, Trisha; Sendilnathan, Arun; Palackdharry, Sarah; Pease, Nicholas; Qualtieri, Julianne; Butler, Randall; Sadraei, Nooshin Hashemi; Morris, John C; Patil, Yash; Wilson, Keith; Mark, Jonathan; Casper, Keith; Takiar, Vinita; Lane, Adam; Privette Vinnedge, Lisa (2018. )Decreased plasma DEK Oncogene Levels Correlate with p16-Negative Disease and Advanced Tumor Stage in a Case-Control Study of Patients with Head and Neck Squamous Cell Carcinoma.Translational oncology, ,11 (1 ),168-174

Karim, Nagla Abdel; Schuster, James; Eldessouki, Ihab; Gaber, Ola; Namad, Tariq; Wang, Jiang; Xie, Changchun; Morris, John C (2018. )Pulmonary sarcomatoid carcinoma: University of Cincinnati experience.Oncotarget, ,9 (3 ),4102-4108

Haugen, Bryan R; Sawka, Anna M; Alexander, Erik K; Bible, Keith C; Caturegli, Patrizio; Doherty, Gerard M; Mandel, Susan J; Morris, John C; Nassar, Aziza; Pacini, Furio; Schlumberger, Martin; Schuff, Kathryn; Sherman, Steven I; Somerset, Hilary; Sosa, Julie Ann; Steward, David L; Wartofsky, Leonard; Williams, Michelle D (2017. )American Thyroid Association Guidelines on the Management of Thyroid Nodules and Differentiated Thyroid Cancer Task Force Review and Recommendation on the Proposed Renaming of Encapsulated Follicular Variant Papillary Thyroid Carcinoma Without Invasion to Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features.Thyroid : official journal of the American Thyroid Association, ,27 (4 ),481-483

Agarwal, Rishi; Wang, Jiang; Wilson, Keith; Barrett, William; Morris, John C (2016. )Response to Targeted Therapy in BRAF Mutant Anaplastic Thyroid Cancer.Journal of the National Comprehensive Cancer Network : JNCCN, ,14 (10 ),1203-1207

Ghose, Abhimanyu; Morris, John C; Breneman, John C; Essell, James; Wang, Jiang; Benzaquen, Sadia Medulloblastoma in an Adult With Late Extraneural Metastases to the Mediastinum.Journal of investigative medicine high impact case reports, ,2 (2 ),2324709614532798

Ramlogan-Steel, Charmaine A; Steel, Jason C; Morris, John C (2014. )Lung cancer vaccines: current status and future prospects.Translational lung cancer research, ,3 (1 ),46-52

Alsidawi, S; Morris, J C; Wikenheiser-Brokamp, K A; Starnes, S L; Karim, N A (2013. )Mucoepidermoid carcinoma of the lung: a case report and literature review.Case reports in oncological medicine, ,2013 ,625243

Starnes, Sandra L; Pathrose, Peterson; Wang, Jiang; Succop, Paul; Morris, John C; Bridges, James; Kupert, Elena Y; Anderson, Marshall (2012. )Clinical and molecular predictors of recurrence in stage I non-small cell lung cancer.The Annals of thoracic surgery, ,93 (5 ),1606-12

Presentations

Invited Presentations

John C. Morris, MD (07-24-2009. )Transforming growth factor-betha: A target for cancer therapy .University of Cincinnati, Cincinnati, OH.

John C. Morris, MD (05-20-2009. )Transforming growth factor-beta: A target for cancer immunotherapy .First International Conference on Cancer Immunotherapy and Immunomonitoring, Kiev, Ukraine.

John C. Morris, MD (11-15-2008. )SynCure Cancer Research Foundation:Living with Cancer from Diagnosis to Survivor: "Advances in the Diagnosis and Treatment of Solid Tumor Cancers" .Grand Summit Hotel, Summit, NJ.

John C. Morris, MD (09-11-2008. )Cancer Immunology and Immunotherapy: Realizign the Promise, Immune Modulatory Molecules .Bethesda, MD.

John C. Morris, MD (05-27-2008. )Institut de Recherches Clinique de Montreal (IRCM), Training program in Cancer Research Workshop .Montreal, Canada.

John C. Morris, MD (12-06-2007. )Immunodiagnostics & Immunomonitoring: From Research to Clinic .Washington, DC.

John C. Morris, MD (10-19-2007. )"Receptor-directed therapy of T-cell leukemia and lymphoma" .Washington Hospital Center, Washington, DC.

John C. Morris, MD (09-10-2007. )Session Chairman: Immune Mediated Diseases: From Theory to Therapy .Moscow, Russia.

Honors and Awards

2009 10- Year Federal Service Recognition Certificate

2009 Federal Technology Transfer Award

2008 Federal Technology Transfer Award

2008 NCI Best Case Series Office of Cancer Complementary and Alternative Medicine Nominal Award

2003 NCI Outstanding Mentor Award Nominee

1999 NHGRI Scientific Retreat Poster Presentation Award

1999 NIH "Bench to Bedside" Grant Award "Evaluation of an E1b 55-kD Expressing Replicating Adenovirus Expressing HSV-tk (Ad.OW34) in Advanced Squamous Cell Carcinoma of the Head and Neck"

1994 Solomon R. Berson Teaching Award 1st Runner-up

1992 Mount Sinai Hospital's "Physician of the Year" Award Nominee

1991 One of "The Best Physicians in New York" Listed in New York Magazine

Keywords

Hematology/Oncology, Cancer, Oncology, Head & Neck Cancer, Lung Cancer

Contact Information

Academic - Vontz Center for Molecular Studies
3125 Eden Avenue
Cincinnati  Ohio, 45267
Phone: 513-558-2158
Fax: 513-558-2124
john.morris2@uc.edu